3 results
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Primary objective: To evaluate the safety and tolerability of GSK1795091 when administered in combination with either GSK3174998, GSK3359609, orpembrolizumab.Secondary objectives: * To evaluate the antitumor activity of GSK1795091 when administered…
The objectives of this study are to determine:• The safety and tolerability of trimetazidine in patients with ALS/MND• The change from baseline in oxidative stress markers in patients with ALS/MND after the initiation of trimetazidine• The change…